Core Viewpoint - Haemonetics reported quarterly earnings of $1.1 per share, exceeding the Zacks Consensus Estimate of $1.01 per share, and showing a slight increase from $1.02 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was +8.91%, with the company also surpassing earnings expectations in the previous quarter by +1.64% [2]. - Revenues for the quarter ended June 2025 were $321.39 million, which was 5.97% above the Zacks Consensus Estimate, although it represented a decline from $336.17 million in the same quarter last year [3]. Stock Performance - Haemonetics shares have declined approximately 3% since the beginning of the year, contrasting with a 7.9% gain in the S&P 500 [4]. - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [7]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.16, with projected revenues of $321.11 million, and for the current fiscal year, the EPS estimate is $4.89 on revenues of $1.3 billion [8]. - The outlook for the Medical - Products industry, where Haemonetics operates, is currently in the bottom 37% of Zacks industries, which may impact stock performance [9].

Core Viewpoint - Perrigo reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59 per share, but showing an increase from $0.53 per share a year ago, indicating a -3.39% earnings surprise [1] - The company posted revenues of $1.06 billion for the quarter, missing the Zacks Consensus Estimate by 2.63%, and a slight decrease from $1.07 billion year-over-year [2] Financial Performance - Over the last four quarters, Perrigo has surpassed consensus EPS estimates two times [2] - The company has not been able to beat consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $1.12 billion, and for the current fiscal year, it is $3.04 on revenues of $4.44 billion [7] Stock Performance and Outlook - Perrigo shares have increased by approximately 3.5% since the beginning of the year, compared to the S&P 500's gain of 7.1% [3] - The company's earnings outlook and management's commentary on the earnings call will be crucial for future stock price movements [3][4] - The estimate revisions trend for Perrigo was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Perrigo belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Cresco Labs Inc., is expected to report a quarterly loss of $0.04 per share, with revenues projected to decline by 11.1% year-over-year [9]

Financial Performance - Evolus, Inc. reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -166.67% [1] - The company posted revenues of $69.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 16.33%, compared to year-ago revenues of $66.91 million [2] - Over the last four quarters, Evolus has not surpassed consensus EPS or revenue estimates [2] Stock Performance - Evolus shares have declined approximately 17.5% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current Zacks Rank for Evolus is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $86.76 million, and -$0.11 on revenues of $350.01 million for the current fiscal year [7] - The outlook for the Medical - Products industry, to which Evolus belongs, is currently in the bottom 38% of over 250 Zacks industries, which may impact the stock's performance [8]

Jushi Holdings Inc. (JUSHF) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.09, delivering a surprise of -50%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Jushi Holdings Inc. shares ha ...

Company Performance - InfuSystems Holdings, Inc. reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, and showing a significant increase from earnings of $0.03 per share a year ago, resulting in an earnings surprise of +300.00% [1] - The company posted revenues of $36 million for the quarter ended June 2025, which was a slight miss compared to the Zacks Consensus Estimate by 0.27%, but an increase from year-ago revenues of $33.7 million [2] - Over the last four quarters, InfuSystems has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - InfuSystems Holdings shares have declined approximately 30.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The current Zacks Rank for InfuSystems is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $38.25 million, and for the current fiscal year, it is $0.10 on revenues of $147.05 million [7] - The outlook for the Medical - Products industry, to which InfuSystems belongs, is currently in the bottom 38% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Performance - Zynex Inc. reported a quarterly loss of $0.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, and a significant decline from earnings of $0.04 per share a year ago, indicating an earnings surprise of -60.00% [1] - The company posted revenues of $22.29 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 17.44%, and a substantial decrease from year-ago revenues of $49.88 million [2] - Over the last four quarters, Zynex has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates during the same period [2] Stock Performance - Zynex shares have declined approximately 68.9% since the beginning of the year, contrasting sharply with the S&P 500's gain of 8.2% [3] - The current Zacks Rank for Zynex is 4 (Sell), indicating expectations for the stock to underperform the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $28.13 million, while for the current fiscal year, the estimate is -$0.81 on revenues of $110.3 million [7] - The outlook for the Medical - Products industry, to which Zynex belongs, is currently in the bottom 26% of over 250 Zacks industries, suggesting potential challenges ahead [8]

分组1 - ResMed reported quarterly earnings of $2.55 per share, exceeding the Zacks Consensus Estimate of $2.46 per share, and up from $2.08 per share a year ago, representing an earnings surprise of +3.66% [1] - The company achieved revenues of $1.35 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.87%, compared to $1.22 billion in the same quarter last year [2] - ResMed has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has gained approximately 21.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.2% [3] - The current consensus EPS estimate for the upcoming quarter is $2.49 on revenues of $1.32 billion, and for the current fiscal year, it is $10.46 on revenues of $5.52 billion [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 26% of over 250 Zacks industries, which may impact stock performance [8]

Core Insights - Baxter International reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.60 per share, and down from $0.68 per share a year ago, representing an earnings surprise of -1.67% [1] - The company posted revenues of $2.81 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.28%, and down from $3.81 billion year-over-year [2] - Baxter has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $2.9 billion, and for the current fiscal year, it is $2.50 on revenues of $11.35 billion [7] - The estimate revisions trend for Baxter was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which Baxter belongs, is currently in the bottom 26% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

Core Insights - SNDL Inc. reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.04 per share, marking an earnings surprise of +125.00% [1] - The company generated revenues of $176.9 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.13% and showing an increase from $166.73 million year-over-year [2] - SNDL shares have underperformed the market, losing about 19.6% since the beginning of the year compared to the S&P 500's gain of 8.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $176.04 million, and for the current fiscal year, it is -$0.11 on revenues of $676.58 million [7] - The estimate revisions trend for SNDL was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which SNDL belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Utah Medical Products, Inc. (UTMD) experienced a 3% decline in share price following its earnings report for Q2 2025, contrasting with a 0.6% increase in the S&P 500 index during the same period [1] - The company reported earnings per share (EPS) of 94 cents, a 4% decrease from 98 cents in Q2 2024 [1] Financial Performance - Net sales were $10 million, down 4.3% from $10.4 million in the same quarter last year [2] - Income before tax decreased by 8.9% to $3.8 million, while net income fell 11.7% to $3.1 million compared to $3.5 million in Q2 2024 [2] Sales Trends - Domestic sales increased by 0.6% to $5.9 million, driven by a 10% rise in direct non-Filshie device sales and an 8% increase in Filshie device sales [3] - However, OEM domestic sales plummeted by 38% due to a significant drop in PendoTECH orders [3] - International sales dropped 10.5% to $4.1 million, with direct sales by subsidiaries falling 15.8% [4] Profitability Metrics - Gross profit margin contracted to 56.2% from 60.1% a year earlier, with gross profit declining 10.5% to $5.6 million [5] - Operating income fell 7.1% to $3.2 million, and the operating margin decreased to 32.1% from 33.1% [5] - Net income margin narrowed to 30.6% from 33.2%, influenced by a higher effective tax rate of 20.5% compared to 18% in the previous year [6] Expense Management - Total operating expenses decreased by 14.8% to $2.4 million, with general and administrative expenses dropping 13.6% to $1.7 million [7] - R&D spending saw a significant decline of 47.1% to $0.1 million following the completion of biopharma sensor validation [7] Capital Allocation - The company repurchased 64,988 shares at an average price of $53.67 and paid $1 million in dividends, which accounted for 33% of net income [8] - Cash and investments at the end of the quarter totaled $82.2 million, slightly down from $83 million at the end of 2024 [8] Management Insights - Management attributed revenue decline to the expected drop in PendoTECH sales but highlighted the strength of core direct sales, particularly in the U.S. [9] - Full-year 2025 results are expected to reflect continued weakness in PendoTECH sales, projected to be about $2 million lower than in 2024 [10] - The current trailing twelve-month (TTM) EBITDA stands at $18.6 million, with a target range of $16 million to $18 million for the year [10]